Search

Displaying results 5651 - 5660 of 6949 in total
  1. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.

    Categories: Smoothened Receptor Antagonists
  2. Drug

    Polysorbate 80

    go.drugbank.com/drugs/DB11063
    ApprovedInvestigational

    Polysorbate 80 is an excipient that is used to stabilize aqueous formulations of medications for parenteral administration or vaccinations.

  3. Drug

    AMG-222

    go.drugbank.com/drugs/DB06011
    Experimental

  4. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  5. Drug

    Calcium silicate

    go.drugbank.com/drugs/DB13829
    Investigational

    Categories: Drugs for Acid Related Disorders
  6. Drug

    Aconiazide

    go.drugbank.com/drugs/DB17731
    Experimental

    Categories: Drugs for Treatment of Tuberculosis
  7. Drug

    Macozinone

    go.drugbank.com/drugs/DB14821
    Investigational

    Macozinone is under investigation in clinical trial NCT03036163 (Phase 1 Study of PBTZ169).

    Categories: Drugs for Treatment of Tuberculosis
  8. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

  9. Drug

    EGS21

    go.drugbank.com/drugs/DB05056
    Experimental

    It is a potential therapeutic for treating immune mediated disorders.

  10. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.